PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases.
Based on the Company’s core proprietary ‘Protein Interference’ technology’, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.
In the media
19th November 2019
6 Ways To Finally Drug RAS Oncogenes
all KRAS mutants Carmot Therapeutics : Their CEO will present on how Chemotype Evolution (CE) has enabled novel covalent KRAS G12C inhibitors discovery PhoreMost : Find out how their PROTEINi platform
15th November 2019
PhoreMost and Sentinel Oncology expand partnership to advance novel allosteric PLK1 inhibitor
Nov 15 2019 PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, today announce an expansion of their collaboration to accelerate the progression of
12th November 2019
PhoreMost – Drugging the Undruggable
The company bringing a systematic pipeline of first-in-class drugs to market – Cambridge-based PhoreMost – is at the forefront of discovering and developing the next generation of therapies. The company’s team